Why the study?
Leadless pacemakers have become niche products due to guidelines and restrictions, prompting the need to determine expert consensus on their optimal use in the UK.
This consensus statement provides seven recommendations to optimize and potentially increase the use of leadless pacemakers in the UK.
May guide UK leadless pacemaker implantation; extends expert consensus to inform practice and future trials.
Pacemakers are a key technology in the treatment of bradyarrhythmias. Leadless pacemakers (LP) were introduced to address limitations of transvenous devices. However, guidelines and other restrictions have led to LPs becoming niche products. The aim of this consensus statement was to determine the strength of opinion of UK implantation experts as to how LPs can be more optimally used. Using a modified Delphi approach, a panel of LP experts developed 36 statements that were used to form a survey that was distributed to LP implanters in the UK. Stopping criteria included a 3-month window for response, a minimum 25% response rate and at least 75% of statements achieving the threshold for consensus (agreed at 66%). In all, 31 of 36 statements reached consensus, and 23 of these achieved ≥90% agreement. Five statements did not achieve consensus. On the basis of these results, seven recommendations were proposed. The implementation of these recommendations may increase the use of LPs, with the aim of improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Roberts et al. (2022) studied Bradyarrhythmias. Leadless pacemakers was evaluated on Consensus on statements regarding optimal use of leadless pacemakers. A modified Delphi survey of UK implantation experts achieved consensus on 31 of 36 statements (23 with ≥90% agreement) regarding the optimal use of leadless pacemakers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: